Objetivo: Avaliar se a radioiodoterapia com 131I-metaiodobenzilguanidina (131I-mIBG) aumenta sobrevida de pacientes diagnóstico neuroblastoma, mIBG-ávido, refratários ao tratamento ou alto risco para recidiva, independentemente do estadiamento da doença. Métodos: Revisão sistemática literatura. Consultadas as bases Medline (PUBMED), EMBASE e Cochrane Library, sendo incluídos estudos disponíveis...

m-[l25I]iodobenzylguanidine (m-[125I]MIBG) has been suggested as an alternative to m-[131I]MIBG for the treatment of metastatic neuroblastoma to achieve a higher radiation dose in micrometastases. To compare these two radiopharmaceuticals, a mathematical model was developed in the present study that allows for the calculation of radiation dose rates within small spherical tumors for different d...

OBJECTIVE Neuroblastoma is the third most common malignancy of childhood. 131I-MIBG scintigraphy must be performed in patients with neuroblastoma at the time of staging. The aim of this study is to identify the role of 131I-MIBG scintigraphy in neuroblastoma patients in correlation with other diagnostic modalities for staging of the disease. METHODS Twenty six patients provisionally diagnosed...

Neuroblastoma is the third most common malignancy of childhood. Nowadays, MIBG has become a central procedure for staging and defining extent and location of neuroblastoma tumors. The recommendations of the International Neuroblastoma Staging System (INSS) indicate that MIBG scintigraphy must be performed in patients with neuroblastoma at the time of initial staging and as a followup tool durin...

PURPOSE To assess the efficacy of different schedules for combining external beam radiotherapy (EBRT) with molecular radiotherapy (MRT) using 131I-mIBG in the management of neuroblastoma. MATERIALS AND METHODS BALB/c nu/nu mice bearing SK-N-SH neuroblastoma xenografts were assigned to five treatment groups: 131I-mIBG 24h after EBRT, EBRT 6days after 131I-mIBG, EBRT alone, 131I-mIBG alone and ...

Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand...

Keywords: false-positive result; [131I ]MIBG scan; renal neuroblastomas, and has had only limited success in other tumour types [1,2]. In our patient, the topo-artery stenosis graphic appearance of the MIBG accumulation corresponded exactly to the entire left kidney, as defined by diffuse homogeneously decreased MAG3 perfusion and uptake. Horne et al. supposed this accumulation to Renal history...

UNLABELLED 131I-labeled metaiodobenzylguanidine (MIBG) is an established treatment modality for neuroendocrine tumors. Because of low tumor doses, it has a predominantly palliative character. Our approach was to investigate whether intraarterial application of 131I-MIBG has the potential to enhance tumor uptake. METHODS Seventeen patients with primary or metastasized neuroendocrine tumors rec...

The prognosis for relapsing or refractory neuroblastoma (NB) remains dismal, with a five-year disease-free survival of < 20%, and no effective salvage treatment has been identified so far. 131I-metaiodobenzylguanidine (131I-MIBG) has come to play an essential role in the imaging and therapy of NB over the past 30 years. The role of 131I-MIBG in the treatment of NB is continually expanding. 131I...

BACKGROUND Palliative treatment ore remains a significant clinical problem. OBJECTIVES To retrospectively determine the clinical response to 131I-MIBG therapy at low doses in patients with refractory neuroblastoma. METHODS We performed a retrospective chart review of 10 patients with neuroblastoma treated with 1311-MIBG at Rambam Health Care Campus from 1994 to 2012. Clinical data, number o...